Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of AG-236 in Healthy Participants
NCT07075640Phase 1Active, not recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Jul 2025
- Primary completion
- Feb 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALN-TMP (3 arms), sponsored by Agios Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Jul 2025; status: active, not recruiting.
02
Drugs
ALN-TMP
Beyond the preview
Go deeper on NCT07075640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075640.